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CASE STUDY
Imatinib could be a new strategy 
for pulmonary hypertension caused 
by pulmonary tumor thrombotic 
microangiopathy in metastatic breast cancer
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Abstract 
Introduction: Pulmonary tumor thrombotic microangiopathy (PTTM) is rare, cancer-related pulmonary complication 
leading to hypoxia, pulmonary hypertension, and heart failure. The standard treatment for PTTM is not established. 
However, imatinib, a tyrosine kinase inhibitor of the PDGF receptor, may cause regression of pulmonary hypertension 
and pulmonary artery remodeling in PTTM.
Case descriptions: We report two cases of PTTM who received an anti-PDGF agent of imatinib for PTTM developed 
during chemotherapy for metastatic breast cancer. Case 1: 61-year-old woman who underwent resection of the left 
breast and axillary lymph node dissection and received adjuvant chemotherapy (CAF followed by docetaxel), then 
endocrine therapy for 5 years. Twelve years after surgery, multiple bone and mediastinal lymph node metastases 
occurred. She was under treatment with eribulin for one year but admitted because of rapid progressing dyspnea. 
Case 2: 45-year-old woman with metastatic breast cancer in multiple bones was under treatment for 5 years. Receiv-
ing capecitabine, she suffered from dyspnea for 2 months, she was admitted to our hospital with diagnosis of severe 
hypoxia. In both cases, the wedged pulmonary arterial blood cell sampling revealed cytologically malignant cells 
which confirmed the diagnosis of PTTM. They were treated with imatinib, which alleviated pulmonary hypertension. 
However, they died due to progression of metastatic breast cancer.
Discussion and Evaluation: Single use of imatinib did not showed sufficient efficacy. It is necessary to conduct a 
well-designed clinical trial using chemotherapies combined with imatinib for PTTM.
Conclusions: Imatinib, which alleviated pulmonary hypertension, could be a new strategy for pulmonary tumor 
thrombotic microangiopathy in patient with metastatic breast cancer.
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Background
Pulmonary tumor thrombotic microangiopathy (PTTM) 
is very rare cancer-related complication that causes 
pulmonary hypertension, heart failure and hypoxia. 
Although the standard treatment for PTTM is not estab-
lished, imatinib, a tyrosine kinase inhibitor of the PDGF 
receptor, may cause regression of pulmonary hyperten-
sion and pulmonary artery remodeling in PTTM. We 
report two cases of PTTM in patients with metastatic 
breast cancer who receiving imatinib for pulmonary 
hypertension caused by PTTM.
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Case presentation
Case1
The patient was a 61-year-old woman who had under-
gone resection of the left breast and axillary lymph node 
dissection. She received adjuvant chemotherapy (CAF; 
cyclophosphamide 500  mg/m2, doxorubicin 50  mg/m2, 
fluoropyrimidine 500  mg/m2 followed by docetaxel, then 
tamoxifen followed by anastrozole for a total of 5  years. 
Twelve years after surgery, multiple bone and mediasti-
nal lymph node metastases were detected. She was under 
treatment with eribulin for 1  year but admitted because 
of rapid progressing dyspnea. Although the enhanced 
computed tomography showed no pulmonary embolism, 
ventilation-perfusion scintigraphy demonstrated multi-
ple small peripheral perfusion defects in both lungs. A 
transthoracic echocardiogram showed severe pulmo-
nary hypertension with estimated right ventricular sys-
tolic pressure of 76  mmHg. She was transferred to the 
Department of Cardiovascular Medicine, the wedged 
pulmonary arterial blood cell sampling showed clusters 
of malignant cells with high nuclear/cytoplasm ratio, 
focal glandular structures which confirmed the diagno-
sis of PTTM (Fig. 1a). Pulmonary arterial pressure (PAP) 
was measured at 93/39(60) mmHg, the cardiac index (CI) 
was 1.63 L/min/m2 and pulmonary vascular resistance 
elevated to 1947 dyne·s/cm5. Nine days after administer-
ing the imatinib (200  mg/day), the PAP was reduced to 
87/30(50) mmHg, and the CI was improved to 2.83 L/min/
m2. We increased the dose of imatinib to 400 mg, then the 
CI was improved to 2.97  L/min/m2 though the PAP was 
slightly elevated to 95/44(56) mmHg (Table 1). The patient 
died due to progression of breast cancer itself 54 days after 
her initial admission. In autopsy, an embolus of tumor 
cells was noted in the pulmonary artery and the lumen of 
the pulmonary artery was severely narrowed. Tumor cells 
were immunohistochemically positive for PDGF-B.
Case2
A 45-year-old woman with metastatic breast cancer in 
multiple bones. The core needle biopsy from primary 
breast tumor revealed that invasive ductal carcinoma 
with nuclear grade1, ER+  , PgR+  , HER2:0. She was 
under treatment for 5  years (Tamoxifen, FAC therapy; 
Cyclophosphomide 500  mg/m2, Doxorubicin 50  mg/
m2, Fluorouracil 500  mg/m2 for 7  months, triweekly 
docetaxel for 11  months, anastrozole and leuprore-
lin for 21  months, and capecitabine for 8  months with 
zoledronic acid. After she suffered from dyspnea for 
2  months, she was admitted to our hospital with diag-
nosis of severe hypoxia. Although the enhanced com-
puted tomography did not show pulmonary embolism, 
the scintigraphy demonstrated patchy flow reduction in 
both lungs. The test of blood coagulation suggested the 
micro-thromboembolism. Hypoxia rapidly progressed 
even after anticoagulation therapy. On the 21st  day 
after admission, she was transferred to the Department 
of Cardiovascular Medicine for a more precise diagno-
sis and intensive treatment. Wedged pulmonary arte-
rial blood cell sampling revealed cytologically malignant 
cells which confirmed the diagnosis of PTTM (Fig. 1b). 
The serum of the patient exhibited a high level of plate-
let-derived growth factor (PDGF), which produced 
by tumor cells, would promote vascular remodeling. 
Pulmonary arterial pressure (PAP) was measured at 
Fig. 1 Cytology from pulmonary artery (a case 1, b case 2). The cytology of the blood in the pulmonary artery revealed adenocarcinoma cells 
(Papanicolaou stain)
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47/18(27) mmHg, and the cardiac index (CI) was 2.98 L/
min/m2. Pulmonary vascular resistance elevated to 490 
dyne·s/cm5. Imatinib (200  mg/day) was administered 
as a clinical trial immediately. Seven days administer-
ing imatinib, the PAP was still 45/22(30)  mmHg, but 
the CI was improved to 3.65  L/min/m2 and pulmonary 
vascular resistance reduced to 400 dyne·s/cm5 (Table 1). 
Although we increased the dose of imatinib to 400 mg, 
she died of respiratory insufficiency in 24 days from her 
initial admission.
Discussion
We demonstrated that imatinib could alleviated pulmo-
nary hypertension in two patient with PTTM. PTTM is 
one of the very rare cancer-related pulmonary compli-
cations, leading to pulmonary hypertension, heart fail-
ure and hypoxia. Von Herbay et  al. reported 21 cases 
of PTTM in 630 carcinoma autopsies, the incidence 
of PTTM was 3.3  % (von Herbay et  al. 1990). In their 
report, all 21 cases had carcinoma with distant metasta-
ses and 19 cases had adenocarcinomas of various organs. 
Although the stomach cancer was the most common, 
there was two cases of breast cancer. The other previ-
ous reports by Okubo et  al. showed six cases of PTTM 
in 37 gastric carcinoma autopsies (Okubo et  al. 2011). 
The mechanism of PTTM is still unclear. However, the 
morphometric and immunohistochemical analyses have 
been developed recently. There are two hypotheses for 
the development of pulmonary hypertension and right-
heart failure, the dysregulation of signaling pathways 
which respond to the presence of an embolic cell or other 
intravascular insult, causes vascular remodeling and the 
other hypothesis proposes that tumor emboli occlude 
the pulmonary arterial bed and increase pulmonary vas-
cular resistance (Roberts et  al. 2003). Von Herbay et  al. 
revealed that tumor cells invaded the pulmonary vascu-
lar system and occluded the small arteries and arterioles 
that activate coagulation systems, releasing inflammatory 
mediators and growth factors, which induced both local 
activation of coagulation and fibrocellular intimal pro-
liferation (von Herbay et al. 1990; Sakashita et al. 2007). 
Okubo et al. also reported the morphometric analysis of 
pulmonary arteries and suggested that pulmonary arte-
rial remodeling induced by carcinoma cell adhesion onto 
the endothelium affected the status of pulmonary hyper-
tension. Some previous studies revealed that cancer cells 
produced the molecules that cause PTTM, which con-
tains the tissue factor (Okubo et  al. 2011), the vascular 
endothelial growth factor (Sakashita et  al. 2007; Chinen 
et al. 2010; Takahashi et al. 2009; Yokomine et al. 2010) 
and osteopontin (Takahashi et  al. 2009; Denhardt et  al. 
2001). The platelet-derived growth factor (PDGF) and 
PDGF receptor (PDGFR) is also important molecular 
agents in development of pulmonary hypertension in 
patients with PTTM (Abe et al. 2013). von Herbay et al. 
(1990) reported that attachment of tumor cell emboli 
might damage endothelial cells, releasing PDGF (von 
Herbay et  al. 1990). Yokomine et  al. reported an autop-
sied case of PTTM with gastric carcinoma that expressed 
the PDGF and PDGFR in cancer cells. They also revealed 
that the overexpression of PDGF was detected in alveo-
lar macrophages and PDGFR in intimal mesenchymal 
cells in the pulmonary arterial wall, which suggested the 
contribution of the activated alveolar macrophages to 
the onset of PTTM (Yokomine et al. 2010). The standard 
treatment for PTTM has not been established. However, 
imatinib, a tyrosine kinase inhibitor of the PDGF recep-
tor, may cause regression of pulmonary hypertension 
and pulmonary artery remodeling in PTTM (Ogawa 
et al. 2013). In our cases, imatinib was administered as a 
clinical trial, approved by the Institutional Review Board 
of the University of Tokyo Hospital. Although imatinib 
alleviated pulmonary hypertension and the cardiac index 
temporarily improved after administration of imatinib 
in both cases, they died due to progression of metastatic 
breast cancer. Single use of imatinib did not showed suf-
ficient efficacy to suppress the disease progression of 
breast cancer itself. Therefore, it is necessary to establish 
a new strategy for PTTM in metastatic breast cancer, 
using the combination of imatinib and the other chemo-
therapies. However, there are some important problems 
to establish this new strategy.
The first is that the combination of imatinib and the 
other chemotherapies for the treatment of metastatic 
Table 1 The result of catheterization study in case1 and case2
Case 1 Case 2
Day 1 Day 7 Day 22 Day 1 Day 7
Medication None Imatinib 200 mg Imatinib 400 mg None Imatinib 200 mg
PAP (mmHg) 93/39 (60) 87/30 (50) 95/40 (56) 47/18 (29) 45/22 (30)
CI (L/min/m2) 1.63 2.83 2.97 2.98 3.65
PVR (dyne·s/cm2) 1947 914 1037 490 410
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breast cancer have not been established and their safety 
and efficacy are unclear. Treatment with a combination 
of imatinib and cytotoxic chemotherapies have been 
reported in the previous several articles. Kumar et al. also 
reported two cases of patients with synchronous gastro-
intestinal stromal tumor (GIST) and colorectal adeno-
carcinoma (Kumar et  al. 2011). They received FOLFOX 
chemotherapy for colon cancer while administering 
imatinib (400 mg/day) and did not experience unexpected 
toxictity from either the imatinib or chemotherapy. 
Uemura et  al. reported secondary chronic myelogenous 
leukemia following postoperative S-1 (80  mg/day) ther-
apy for advanced gastric cancer (Uemura et  al. 2010). 
Although skin eruption, palpebral edema and appetite 
loss were appeared after weeks starting imatinib therapy, 
these symptoms were alleviated when he stopped taking 
imatinib. Furthermore, the results of PhaseI and II trial 
of combination of imatinib and chemotherapy have been 
reported recently. Lin et al. showed a phaseI trial of doc-
etaxel/estramustine/imatinib in patients with hormone-
refractory prostate cancer (Lin et  al. 2007). Thirteen 
patients with hormone-refractory metastatic prostate 
cancer were treated every 21  days with fixed doses of 
estramustine (280 mg orally 3 times a day on days 1–5), 
imatinib (400  mg orally daily on days 1–21) and doc-
etaxel, in which cohorts of 3–6 patients were enrolled 
to receive escalating doses of docetaxel on day 2 from 
50 to 60 to 70 mg/m2. On dose level 3 (docetaxel 70 mg/
m2 and imatinib 400 mg daily), grade 3 elevations of pro-
thrombin time in two patients. Although the protocol 
was amended to include an intermediate dose level (doc-
etaxel 60 mg/m2 and imatinib 300 mg daily), there were 
five unacceptable toxicities (2 cerebrovascular accidents, 
one myocardial infarction, one mesenteric ischemia, 
and 1 deep venous thrombosis) in 13 patients, and two 
of those toxicities resulted in death. Another phaseIdose-
escalation study of imatinib mesylate plus capecitabine in 
advanced solid tumor was reported (Dugan et al. 2010). 
In their study, 24 patients with advanced solid tumors 
were treated with capecitabine twice daily on days 1–14 
and imatinib mesylate once daily on a 21-day cycle. Six 
patients who were treated with capecitabine at 1000 mg/
m2 and imatinib mesylate 300  mg, had unacceptable 
toxicity due to grade 2 intolerable hand–foot syndrome 
and/or grade 2 and grade 3 diarrhea. These full doses of 
capecitabine and imatinib mesylate were not tolerable. 
Although Doses were subsequently reduced to capecit-
abine at 750  mg/m2 and imatinib mesylate at 300  mg, 
adverse events greater than or equal to grade 3 included 
anemia, diarrhea, dysuria, hypophosphatemia and ver-
tigo. There is a result of multi-institutional phase 2 study 
of imatinib mesylate and gemcitabine for first-line treat-
ment of advanced pancreatic cancer (Moss et  al. 2012). 
Gemcitabine was given at 1200 mg/m2 on days 3 and 10. 
Imatinib (400 mg) was taken orally on days 1 to 5 and 8 
to 12 of a 21-day cycle. Forty-four patients were enrolled 
and the median number of cycles completed was three. 
Common adverse effects included neutropenia, nau-
sea, anemia, and fatigue. 50  % of patients had grade 3 
or higher neutropenia and 17  % had grade 3 or higher 
thrombocytopenia. The significant nonhematologic tox-
icity related to treatment were grade 3 or higher dehy-
dration in 9 %, grade 3 or higher rash in 9 %, grade 3 or 
higher fatigue in 6 %, grade 3 or higher nausea in 6 %, and 
grade 3 or higher renal failure in 2  %. Clinically signifi-
cant grade 1 and 2 toxicities included edema in 4 % and 
rash in 6  %. Overall, half of the patients required dose 
reduction.
The other problem is that the patient with PTTM 
generally have not been able to tolerate chemotherapy 
at symptom onset because of poor physical condition. 
Therefore, the combination therapy of imatinib and 
chemotherapy might not be tolerable for the patients 
with PTTM. It is necessary to conduct a well-designed 
clinical trial to evaluate the use of chemotherapies com-
bined with imatinib for PTTM.
Conclusion
Imatinib, which alleviated pulmonary hypertension, 
could be a new strategy for pulmonary tumor thrombotic 
microangiopathy in patient with metastatic breast cancer.
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